Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Pacific Biosciences, BioEcho, Twist Bioscience, Arrayjet, More

NEW YORK – Pacific Biosciences said this week that it is supporting Canada's Hospital for Sick Children (SickKids) in using HiFi whole-genome sequencing to identify genetic variants associated with medical and developmental conditions. SickKids will examine samples that were previously analyzed with short-read sequencing but where the analysis did not identify a disease-causing variant. 

BioEcho Life Sciences, a German nucleic acid purification and sample prep company, this week announced a minority investment from Ampersand Capital Partners. Financial details were not disclosed. In a statement, BioEcho said it will use the funding to support the launch of several new kits and expand its direct sales force, among other worldwide growth initiatives. 

Twist Bioscience said this week that is has joined the Digital Preservation Coalition's supporter program. The organization works to deliver long-term access to digital content and services. Twist has been working on DNA-based data storage applications for its synthetic oligonucleotides. 

Scottish microarray technology company Arrayjet said this week that it has formed a US subsidiary of the same name that will support US customers in research, pharma, and diagnostics. The company sells liquid handling and bioprinting equipment based on its patented, non-contact inkjet technology and offers contract research and manufacturing services for microarray and high-throughput screening applications. 

Caris Life Sciences said this week that the Tampa General Hospital Cancer Institute has joined the Caris Precision Oncology Alliance, a worldwide network of cancer centers that collaborate to advance precision oncology and biomarker-driven research. The network now comprises 59 cancer centers and academic institutions. Members have early access to Caris' database and artificial intelligence platform to establish evidence-based standards for cancer profiling and molecular testing in oncology. 

Mission Bio said this week that its first center of excellence, aimed at developing best practices for integrating its Tapestri platform into solid tumor research, will be located at Memorial Sloan Kettering Cancer Center. Jorge Reis-Filho, MSK's director of experimental pathology, will run the center. His lab plans to develop academic and industrial best practices using single-cell DNA profiling to observe tumor heterogeneity and clonal architecture in solid cancers. His team will work closely with Mission Bio’s R&D team to improve nuclei extraction protocols, roll out new virtual panel content for BRCA-mutant cancers and other cancer types, and enhance copy number variation analysis. 

Indian genomics company Mapmygenome said this week that it opened a new laboratory, called "Genomics Experience Center," in Bengaluru on March 1. The new center, which is certified by the National Accreditation Board for Testing and Calibration Laboratories and the Indian Council of Medical Research, will provide genetic testing, genetic counseling, blood tests, health screening tests, antibody tests, and COVID-19 RT-PCR tests and will complement Mapmygenome's existing laboratory services in Hyderabad and Delhi. The company's flagship product, Genomepatri, analyses an individual's DNA to assess genetic risk for certain conditions, drug efficacy, and drug sensitivities. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.